Response of thyrotropin to thyrotropin-releasing hormone as predictor of treatment outcome. Prediction of recovery and relapse in treatment with antidepressants and neuroleptics

Arch Gen Psychiatry. 1986 Sep;43(9):861-8. doi: 10.1001/archpsyc.1986.01800090047007.


We determined whether the response of thyrotropin (TSH) to thyrotropin-releasing hormone could predict the outcome of treatment with antidepressant and neuroleptic drugs. We studied 114 female patients diagnosed as having major and minor depressive, manic, schizoaffective, and schizophrenic disorders. A blunted TSH response (less than 5 microU/mL [less than 5 mU/L]) at admission was associated with recovery after nine weeks of inpatient treatment using clomipramine hydrochloride for depression and haloperidol for psychosis. A blunted TSH response at discharge was associated with early relapse in depressives receiving clomipramine maintenance therapy. Our findings support the notion that the thyrotropin-releasing hormone test is a "state" marker that may be of use in predicting the outcome of treatment with antidepressant and neuroleptic drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antidepressive Agents / therapeutic use
  • Antipsychotic Agents / therapeutic use
  • Depressive Disorder / diagnosis
  • Depressive Disorder / drug therapy
  • Female
  • Humans
  • Lithium / therapeutic use
  • Lithium Carbonate
  • Male
  • Middle Aged
  • Outcome and Process Assessment, Health Care
  • Probability
  • Psychiatric Status Rating Scales
  • Psychotic Disorders / diagnosis
  • Psychotic Disorders / drug therapy*
  • Recurrence
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy
  • Thyrotropin / blood*
  • Thyrotropin-Releasing Hormone*


  • Antidepressive Agents
  • Antipsychotic Agents
  • Lithium Carbonate
  • Thyrotropin-Releasing Hormone
  • Thyrotropin
  • Lithium